(INNS)
ROSMANTUZUMAB(SLE)
ROSMANTUZUMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS RSPO3 (R-SPONDIN 3, THROMBOSPONDIN TYPE I (TSP1) DOMAIN CONTAINING PROTEIN 2, THSD2)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-447) [HUMANIZED VH (HOMO SAPIENS IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -HOMO SAPIENS IGHG1*03, (CH1 (118- 215), HINGE (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-218') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') - HOMO SAPIENS IGKC*01, KM3 (112'-218')]; DIMER (226- 226":229-229")-BISDISULFIDE, RECOMMENDED INN: LIST 77(WHO)
ROSMANTUZUMABUM(INN)